Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMRx2 triple-combination versus dual combinations for hypertension
2020-004196-40Phase 3Terminated
- Sponsor
- George Medicines
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telmisartan + amlodipine + indapamide, telmisartan, amlodipine and indapamide in hypertension (HTN) (4 arms), sponsored by George Medicines. Primary endpoint: Change in home seated mean systolic blood pressure. Started Nov 2020; status: terminated.
02
Drugs
telmisartan + amlodipine + indapamidetelmisartanamlodipineindapamide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2020-004196-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004196-40.